Real-World Outcomes of Sequential BCMA-directed therapies inRelapsed Refractory Multiple Myeloma After Belantamab Exposure

Prerna Mewawalla; Rachel Dileo; Yue Yin; Christopher Strouse; Hira Shaikh; James A Davis; Omar Alkharabsheh; Aliya Rashid; Nausheen Ahmed; Al-Ola Abdallah; Hamza Hashmi

doi:10.1016/j.clml.2025.06.015

$Real-World Outcomes of Sequential BCMA-directed therapies inRelapsed Refractory Multiple Myeloma After Belantamab Exposure$

Journal article

Peer reviewed

Real-World Outcomes of Sequential BCMA-directed therapies inRelapsed Refractory Multiple Myeloma After Belantamab Exposure

Prerna Mewawalla, Rachel Dileo, Yue Yin, Christopher Strouse, Hira Shaikh, James A Davis, Omar Alkharabsheh, Aliya Rashid, Nausheen Ahmed, Al-Ola Abdallah, …

Clinical lymphoma, myeloma and leukemia, Vol.25(12), pp.e1007-e1013

12/2025

DOI: 10.1016/j.clml.2025.06.015

PMID: 40681433

View Online

Abstract

While B cell maturation antigen (BCMA) directed therapies are increasingly utilized for multiple myeloma, outcomes with sequential therapies with BCMA directed treatments remains an area of active investigation. In this multicenter retrospective analysis, we evaluated the real-world outcomes of patients treated with BCMA directed therapies including CAR T and bispecific antibody (BsAb) following progression on an antibody drug conjugate belantamab mafodotin. A total of 23 patients (14 CAR T, 9 BsAb), were included in the analysis. The median patient age was 68 (range 37-82) years with 43% with high-risk cytogenetics, 87% had received at least ≥4 prior lines of treatment, and 35% had extra medullary disease at the time of treatment. The overall response rate (ORR) for the entire population was 65%, 44% in the BsAb and 79% in the CAR-T subgroup. With a median follow up of 24 months, median PFS and OS were 5 (2-10) months and 28 (16-NR) months, respectively. There was no difference in median PFS between patients who received a BsAb (5 mos, range 2-10) versus CAR T (7 mos range 2-9) (p= 0.8) or received BCMA directed therapy < 6 months (5 mos, range 3-9) versus ≥ 6 month post belantamab (7 mos, range 2-10) (p= 0.8). Treatment with BCMA directed BsAb or CAR T remains feasible for RRMM patients after progression on belantamab, However, outcomes in general remain inferior compared to those without prior BCMA exposure and were not affected by choice of therapy or time since last BCMA exposure.

BCMA

belanatamab

multiple myeloma

refractory

Relapsed

sequential

Details

Title: Subtitle: Real-World Outcomes of Sequential BCMA-directed therapies inRelapsed Refractory Multiple Myeloma After Belantamab Exposure
Creators: Prerna Mewawalla - Allegheny Health Network
Rachel Dileo - Allegheny Health Network
Yue Yin - Allegheny-Singer Research Institute
Christopher Strouse - University of Iowa
Hira Shaikh - University of Iowa
James A Davis - Medical University of South Carolina
Omar Alkharabsheh - University of South Alabama
Aliya Rashid - The University of Kansas Cancer Center
Nausheen Ahmed - The University of Kansas Cancer Center
Al-Ola Abdallah - The University of Kansas Cancer Center
Hamza Hashmi - Medical University of South Carolina
Resource Type: Journal article
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.25(12), pp.e1007-e1013
DOI: 10.1016/j.clml.2025.06.015
PMID: 40681433
NLM abbreviation: Clin Lymphoma Myeloma Leuk
ISSN: 2152-2650
Publisher: Elsevier Inc
Language: English
Electronic publication date: 06/2025
Date published: 12/2025
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984843595102771

Metrics

73 Record Views